Cyclin E overexpression confers resistance to trastuzumab through noncanonical phosphorylation of SMAD3 in HER2+ breast cancer

References

• Siegel RL, Miller KD, Jemal A. Cancer statistics, 2016. CA Cancer J Clin. 2016;66(1):7–30. doi:10.3322/caac.21332. PubMed PMID: 26742998.
   PubMed Web of Science ®Google Scholar
• Nahta R, Yu D, Hung MC, Hortobagyi GN, Esteva FJ. Mechanisms of disease: understanding resistance to HER2-targeted therapy in human breast cancer. Nat Clin Pract Oncol. 2006;3(5):269–280. doi:10.1038/ncponc0509. PubMed PMID: 16683005.
   PubMedGoogle Scholar
• Piccart-Gebhart MJ, Procter M, Leyland-Jones B, Goldhirsch A, Untch M, Smith I, Gianni L, Baselga J, Bell R, Jackisch C, et al. Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N Engl J Med. 2005;353(16):1659–1672. Epub 2005/ 10/21. doi: 10.1056/NEJMoa052306. PubMed PMID: 16236737.
   PubMed Web of Science ®Google Scholar
• Hudis CA. Trastuzumab — mechanism of action and use in clinical practice. N Engl J Med. 2007;357(1):39–51. doi:10.1056/NEJMra043186. PubMed PMID: 17611206.
   PubMed Web of Science ®Google Scholar
• Slamon DJ, Leyland-Jones B, Shak S, Fuchs H, Paton V, Bajamonde A, Fleming T, Eiermann W, Wolter J, Pegram M, et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med. 2001;344(11):783–792. doi:10.1056/NEJM200103153441101. PubMed PMID: 11248153.
   PubMed Web of Science ®Google Scholar
• Stern HM. Improving treatment of HER2-positive cancers: opportunities and challenges. Sci Transl Med. 2012;4(127):127rv2. doi:10.1126/scitranslmed.3001539. PubMed PMID: 22461643.
   PubMed Web of Science ®Google Scholar
• Baselga J. Clinical trials of herceptin(trastuzumab). Eur J Cancer. 2001;37(Suppl 1):S18–24. PubMed PMID: 11167087.
   PubMedGoogle Scholar
• Nahta R, Esteva FJ. HER2 therapy: molecular mechanisms of trastuzumab resistance. Breast Cancer Res. 2006;8(6):215. doi:10.1186/bcr1612. PubMed PMID: 17096862; PMCID: PMC1797036.
   PubMed Web of Science ®Google Scholar
• Berns K, Horlings HM, Hennessy BT, Madiredjo M, Hijmans EM, Beelen K, Linn SC, Gonzalez-Angulo AM, Stemke-Hale K, Hauptmann M. A functional genetic approach identifies the PI3K pathway as a major determinant of trastuzumab resistance in breast cancer. Cancer Cell. 2007;12(4):395–402.
   PubMed Web of Science ®Google Scholar
• Nagata Y, Lan K-H, Zhou X, Tan M, Esteva FJ, Sahin AA, Klos KS, Li P, Monia BP, Nguyen NT. PTEN activation contributes to tumor inhibition by trastuzumab, and loss of PTEN predicts trastuzumab resistance in patients. Cancer Cell. 2004;6(2):117–127.
   PubMed Web of Science ®Google Scholar
• Nahta R, Yuan LX, Zhang B, Kobayashi R, Esteva FJ. Insulin-like growth factor-I receptor/human epidermal growth factor receptor 2 heterodimerization contributes to trastuzumab resistance of breast cancer cells. Cancer Res. 2005;65(23):11118–11128.
   PubMed Web of Science ®Google Scholar
• Arteaga CL, Engelman JA. ERBB receptors: from oncogene discovery to basic science to mechanism-based cancer therapeutics. Cancer Cell. 2014;25(3):282–303.
   PubMed Web of Science ®Google Scholar
• Mittendorf EA, Liu Y, Tucker SL, McKenzie T, Qiao N, Akli S, Biernacka A, Liu Y, Meijer L, Keyomarsi K, et al. A novel interaction between HER2/neu and cyclin E in breast cancer. Oncogene. 2010;29(27):3896–3907. doi:10.1038/onc.2010.151. PubMed PMID: 20453888; PMCID: PMC2900397.
   PubMed Web of Science ®Google Scholar
• Asghar U, Witkiewicz AK, Turner NC, Knudsen ES. The history and future of targeting cyclin-dependent kinases in cancer therapy. Nat Rev Drug Discov. 2015;14(2):130–146. doi:10.1038/nrd4504. PubMed PMID: 25633797; PMCID: PMC4480421.
   PubMed Web of Science ®Google Scholar
• Tarasewicz E, Hamdan R, Straehla J, Hardy A, Nunez O, Zelivianski S, Dokic D, Jeruss JS. CDK4 inhibition and doxorubicin mediate breast cancer cell apoptosis through Smad3 and survivin. Cancer Biol Ther. 2014;15(10):1301–1311. doi:10.4161/cbt.29693. PubMed PMID: 25006666; PMCID: PMC4130723.
   PubMed Web of Science ®Google Scholar
• Tarasewicz E, Rivas L, Hamdan R, Dokic D, Parimi V, Bernabe BP, Thomas A, Shea LD, Jeruss JS. Inhibition of CDK-mediated phosphorylation of Smad3 results in decreased oncogenesis in triple negative breast cancer cells. Cell Cycle. 2014;13(20):3191–3201. doi:10.4161/15384101.2014.950126. PubMed PMID: 25485498; PMCID: PMC4614520.
   PubMed Web of Science ®Google Scholar
• Thomas AL, Lind H, Hong A, Dokic D, Oppat K, Rosenthal E, Guo A, Thomas A, Hamden R, Jeruss JS. Inhibition of CDK-mediated Smad3 phosphorylation reduces the Pin1-Smad3 interaction and aggressiveness of triple negative breast cancer cells. Cell Cycle. 2017;16(15):1453–1464. doi:10.1080/15384101.2017.1338988.
   PubMed Web of Science ®Google Scholar
• Sherr CJ, Roberts JM. CDK inhibitors: positive and negative regulators of G1-phase progression. Genes Dev. 1999;13(12):1501–1512. PubMed PMID: 10385618.
   PubMed Web of Science ®Google Scholar
• Tarasewicz E, Jeruss JS. Phospho-specific Smad3 signaling: impact on breast oncogenesis. Cell Cycle. 2012;11(13):2443–2451. doi:10.4161/cc.20546. PubMed PMID: 22659843; PMCID: PMC3404875.
   PubMed Web of Science ®Google Scholar
• Roberts AB, Tian F, Byfield SD, Stuelten C, Ooshima A, Saika S, Flanders KC. Smad3 is key to TGF-β-mediated epithelial-to-mesenchymal transition, fibrosis, tumor suppression and metastasis. Cytokine Growth Factor Rev. 2006;17(1–2):19–27.
   PubMed Web of Science ®Google Scholar
• Matsuura I, Denissova NG, Wang G, He D, Long J, Liu F. Cyclin-dependent kinases regulate the antiproliferative function of Smads. Nature. 2004;430(6996):226–231. doi:10.1038/nature02650. PubMed PMID: 15241418.
   PubMed Web of Science ®Google Scholar
• Scaltriti M, Eichhorn PJ, Cortes J, Prudkin L, Aura C, Jimenez J, Chandarlapaty S, Serra V, Prat A, Ibrahim YH, et al. Cyclin E amplification/overexpression is a mechanism of trastuzumab resistance in HER2+ breast cancer patients. Proc Natl Acad Sci U S A. 2011;108(9):3761–3766. doi:10.1073/pnas.1014835108. PubMed PMID: 21321214; PMCID: PMC3048107.
   PubMed Web of Science ®Google Scholar
• Chohan TA, Qian H, Pan Y, Chen JZ. Cyclin-dependent kinase-2 as a target for cancer therapy: progress in the development of CDK2 inhibitors as anti-cancer agents. Curr Med Chem. 2015;22(2):237–263. Epub 2014/ 11/12. PubMed PMID: 25386824.
   PubMed Web of Science ®Google Scholar
• Dull T, Zufferey R, Kelly M, Mandel R, Nguyen M, Trono D, Naldini L. A third-generation lentivirus vector with a conditional packaging system. J Virol. 1998;72(11):8463–8471.
   PubMed Web of Science ®Google Scholar
• Decker JT, Hall MS, Penalver-Bernabe B, Blaisdell RB, Liebman LN, Jeruss JS, Shea LD. Design of large-scale reporter construct arrays for dynamic, live cell systems biology. ACS Synth Biol. 2018;7:2063–2073.
   PubMed Web of Science ®Google Scholar
• Decker JT, Hobson EC, Zhang Y, Shin S, Thomas AL, Jeruss JS, Arnold KB, Shea LD. Systems analysis of dynamic transcription factor activity identifies targets for treatment in olaparib resistant cancer cells. Biotechnol Bioeng. 2017;114(9):2085–2095.
   PubMed Web of Science ®Google Scholar
• Bernabé BP, Shin S, Rios PD, Broadbelt LJ, Shea LD, Seidlits SK. Dynamic transcription factor activity networks in response to independently altered mechanical and adhesive microenvironmental cues. Integr Biol. 2016;8(8):844–860.
   Google Scholar
• Smyth GK. Limma: linear models for microarray data. Bioinformatics and computational biology solutions using R and Bioconductor. Springer; 2005. p. 397–420.
   Google Scholar
• Benjamini Y, Hochberg Y. Controlling the false discovery rate: a practical and powerful approach to multiple testing. J R Stat Soc Series B (Methodological). 1995;57:289–300.
   Web of Science ®Google Scholar
• Decker JT, Hall MS, Blaisdell RB, Schwark K, Jeruss JS, Shea LD. Dynamic microRNA activity identifies therapeutic targets in trastuzumab‐resistant HER2+ breast cancer. Biotechnol Bioeng. 2018;115:2613–2623.
   PubMed Web of Science ®Google Scholar
• Mevik B-H, Wehrens R. The pls package: principal component and partial least squares regression in R. J Stat Softw. 2007;18(2):1–24.
   Web of Science ®Google Scholar
• Siletz A, Schnabel M, Kniazeva E, Schumacher AJ, Shin S, Jeruss JS, Shea LD. Dynamic transcription factor networks in epithelial-mesenchymal transition in breast cancer models. PloS One. 2013;8:4.
   Google Scholar
• Haury A-C, Mordelet F, Vera-Licona P, Vert J-P. TIGRESS: trustful inference of gene regulation using stability selection. BMC Syst Biol. 2012;6(1):1.
   PubMedGoogle Scholar
• Breiman L. Random forests. Mach Learn. 2001;45(1):5–32.
   Web of Science ®Google Scholar
• Margolin AA, Nemenman I, Basso K, Wiggins C, Stolovitzky G, Favera RD, Califano A. ARACNE: an algorithm for the reconstruction of gene regulatory networks in a mammalian cellular context. BMC Bioinform. 2006;7(Suppl 1):S7.
   PubMedGoogle Scholar
• Faith JJ, Hayete B, Thaden JT, Mogno I, Wierzbowski J, Cottarel G, Kasif S, Collins JJ, Gardner TS. Large-scale mapping and validation of Escherichia coli transcriptional regulation from a compendium of expression profiles. PLoS Biol. 2007;5(1):e8.
   PubMed Web of Science ®Google Scholar
• Meyer PE, Kontos K, Lafitte F, Bontempi G. Information-theoretic inference of large transcriptional regulatory networks. EURASIP J Bioinform Syst Biol. 2007;2007:8.
   Google Scholar
• Csardi G, Nepusz T. The igraph software package for complex network research. Int J Complex Syst. 2006;1695(5):1–9.
   Google Scholar
• Frame, S, Saladino C, MacKay C, Atrash B, Sheldrake P, McDonald E, Clarke PA, Worman P, Blake D, Zheleva D. Fadraciclib (CYC065), a novel CDK inhibitor, targets key pro-survival and oncogenic pathways in cancer. Plos one. 2020;15(7):e0234103.
   Google Scholar
• Bankhead P, Loughrey MB, Fernández JA, Dombrowski Y, McArt DG, Dunne PD, McQuaid S, Gray RT, Murray LJ, Coleman HG. QuPath: open source software for digital pathology image analysis. Sci Rep. 2017;7(1):1–7.
   PubMed Web of Science ®Google Scholar
• Matsuura I, Denissova NG, Wang G, He D, Long J, Liu F. Cyclin-dependent kinases regulate the antiproliferative function of Smads. Nature. 2004;430(6996):226.
   PubMed Web of Science ®Google Scholar
• Alarcón C, Zaromytidou A-I, Xi Q, Gao S, Yu J, Fujisawa S, Barlas A, Miller AN, Manova-Todorova K, Macias MJ. Nuclear CDKs drive Smad transcriptional activation and turnover in BMP and TGF-β pathways. Cell. 2009;139(4):757–769.
   PubMed Web of Science ®Google Scholar
• Romond EH, Perez EA, Bryant J, Suman VJ, Geyer CE Jr., Davidson NE, Tan-Chiu E, Martino S, Paik S, Kaufman PA, et al. Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med. 2005;353(16):1673–1684. Epub 2005/ 10/21. doi: 10.1056/NEJMoa052122. PubMed PMID: 16236738.
   PubMed Web of Science ®Google Scholar
• Chung A, Cui X, Audeh W, Giuliano A. Current status of anti–human epidermal growth factor receptor 2 therapies: predicting and overcoming herceptin resistance. Clin Breast Cancer. 2013;13(4):223–232.
   PubMed Web of Science ®Google Scholar
• Santa-Maria CA, Nye L, Mutonga MB, Jain S, Gradishar WJ. Management of metastatic HER2-positive breast cancer: where are we and where do we go from here? Oncology. 2016;30:2.
   Web of Science ®Google Scholar
• Sajadimajd S, Yazdanparast R. Sensitizing effect of juglone is mediated by down regulation of Notch1 signaling pathway in trastuzumab-resistant SKBR3 cells. Apoptosis. 2017;22(1):135–144.
   PubMed Web of Science ®Google Scholar
• Huang F, Shi Q, Li Y, Xu L, Xu C, Chen F, Wang H, Liao H, Chang Z, Liu F, et al. HER2/EGFR–AKT signaling switches TGFβ from inhibiting cell proliferation to promoting cell migration in breast cancer. Cancer Res. 2018;78(21):6073–6085. doi:10.1158/0008-5472.can-18-0136.
   PubMed Web of Science ®Google Scholar
• Matsuzaki K, Kitano C, Murata M, Sekimoto G, Yoshida K, Uemura Y, Seki T, Taketani S, Fujisawa J-I, Okazaki K. Smad2 and Smad3 phosphorylated at both linker and COOH-terminal regions transmit malignant TGF-β signal in later stages of human colorectal cancer. Cancer Res. 2009;69(13):5321–5330.
   PubMed Web of Science ®Google Scholar
• Yamagata H, Matsuzaki K, Mori S, Yoshida K, Tahashi Y, Furukawa F, Sekimoto G, Watanabe T, Uemura Y, Sakaida N. Acceleration of Smad2 and Smad3 phosphorylation via c-Jun NH2-terminal kinase during human colorectal carcinogenesis. Cancer Res. 2005;65(1):157–165.
   PubMed Web of Science ®Google Scholar
• Jo E, Park SJ, Choi YS, Jeon W-K, Kim B-C. Kaempferol suppresses transforming growth factor-β1–induced epithelial-to-mesenchymal transition and migration of A549 lung cancer cells by inhibiting Akt1-mediated phosphorylation of Smad3 at threonine-179. Neoplasia. 2015;17(7):525–537.
   PubMed Web of Science ®Google Scholar
• Li L, Cao F, Liu B, Luo X, Ma X, Hu Z. TGF-β induces fascin expression in gastric cancer via phosphorylation of smad3 linker area. Am J Cancer Res. 2015;5(6):1890.
   PubMed Web of Science ®Google Scholar
• Lane HA, Beuvink I, Motoyama AB, Daly JM, Neve RM, Hynes NE. ErbB2 potentiates breast tumor proliferation through modulation of p27(Kip1)-Cdk2 complex formation: receptor overexpression does not determine growth dependency. Mol Cell Biol. 2000;20(9):3210–3223. PubMed PMID: 10757805; PMCID: PMC85615.
   PubMed Web of Science ®Google Scholar
• Nahta R, Takahashi T, Ueno NT, Hung MC, Esteva FJ. P27(kip1) down-regulation is associated with trastuzumab resistance in breast cancer cells. Cancer Res. 2004;64(11):3981–3986. doi:10.1158/0008-5472.CAN-03-3900. PubMed PMID: 15173011.
   PubMed Web of Science ®Google Scholar
• Bitzer M, von Gersdorff G, Liang D, Dominguez-Rosales A, Beg AA, Rojkind M, Böttinger EP. A mechanism of suppression of TGF–β/SMAD signaling by NF-κB/RelA. Genes Dev. 2000;14(2):187–197.
   PubMed Web of Science ®Google Scholar
• Borthwick LA, Gardner A, De Soyza A, Mann DA, Fisher AJ. Transforming growth factor-β1 (TGF-β1) driven epithelial to mesenchymal transition (EMT) is accentuated by tumour necrosis factor α (TNFα) via crosstalk between the SMAD and NF-κB pathways. Cancer Microenvironment. 2012;5(1):45–57. doi:10.1007/s12307-011-0080-9.
   PubMedGoogle Scholar
• Chou J, Lin JH, Brenot A, Kim J-W, Provot S, Werb Z. GATA3 suppresses metastasis and modulates the tumour microenvironment by regulating microRNA-29b expression. Nat Cell Biol. 2013;15:201. doi:10.1038/ncb2672.
   PubMed Web of Science ®Google Scholar
• Fujita H, Kang M, Eren M, Gleaves LA, Vaughan DE, Kume T. Foxc2 is a common mediator of insulin and transforming growth factor β signaling to regulate plasminogen activator inhibitor type I gene expression. Circ Res. 2006;98(5):626–634.
   PubMed Web of Science ®Google Scholar
• Triulzi T, Forte L, Regondi V, Di Modica M, Ghirelli C, Carcangiu ML, Sfondrini L, Balsari A, Tagliabue E. HER2 signaling regulates the tumor immune microenvironment and trastuzumab efficacy. Oncoimmunology. 2019;8(1):e1512942.
   PubMed Web of Science ®Google Scholar
• Cui Y-M, Jiang D, Zhang S-H, Wu P, Ye Y-P, Chen C-M, Tang N, Liang L, Li -T-T, Qi L. FOXC2 promotes colorectal cancer proliferation through inhibition of FOXO3a and activation of MAPK and AKT signaling pathways. Cancer Lett. 2014;353(1):87–94.
   PubMed Web of Science ®Google Scholar
• Mehra R, Varambally S, Ding L, Shen R, Sabel MS, Ghosh D, Chinnaiyan AM, Kleer CG. Identification of GATA3 as a breast cancer prognostic marker by global gene expression meta-analysis. Cancer Res. 2005;65(24):11259–11264.
   PubMed Web of Science ®Google Scholar
• Blokzijl A, Ten Dijke P, Ibáñez CF. Physical and functional interaction between GATA-3 and Smad3 allows TGF-β regulation of GATA target genes. Curr Biol. 2002;12(1):35–45.
   PubMed Web of Science ®Google Scholar
• Chu IM, Lai W-C, Aprelikova O, El Touny LH, Kouros-Mehr H, Green JE. Expression of GATA3 in MDA-MB-231 triple-negative breast cancer cells induces a growth inhibitory response to TGFss. PLoS One. 2013;8:4.
   Web of Science ®Google Scholar
• Zhang L, Zhou F, Ten Dijke P. Signaling interplay between transforming growth factor-β receptor and PI3K/AKT pathways in cancer. Trends Biochem Sci. 2013;38(12):612–620. doi:10.1016/j.tibs.2013.10.001.
   PubMed Web of Science ®Google Scholar
• Scheuer W, Friess T, Burtscher H, Bossenmaier B, Endl J, Hasmann M. Strongly enhanced antitumor activity of trastuzumab and pertuzumab combination treatment on HER2-positive human xenograft tumor models. Cancer Res. 2009;69(24):9330–9336.
   PubMed Web of Science ®Google Scholar
• Rao SS, Stoehr J, Dokic D, Wan L, Decker JT, Konopka K, Thomas AL, Wu J, Kaklamani VG, Shea LD, et al. Synergistic effect of eribulin and CDK inhibition for the treatment of triple negative breast cancer. Oncotarget [Internet]. 2017 2017/10//; 8 48:[83925-39].
   Google Scholar
• Doostan I, Karakas C, Kohansal M, Low KH, Ellis MJ, Olson JA Jr., Suman VJ, Hunt KK, Moulder SL, Keyomarsi K. Cytoplasmic cyclin E mediates resistance to aromatase inhibitors in breast cancer. Clin Cancer Res. 2017;23(23):7288–7300. Epub 2017/ 09/28. doi: 10.1158/1078-0432.ccr-17-1544. PubMed PMID: 28947566; PMCID: PMC5768442.
   PubMed Web of Science ®Google Scholar
• Alexander A, Karakas C, Chen X, Carey JP, Yi M, Bondy M, Thompson P, Cheung KL, Ellis IO, Gong Y, et al. Cyclin E overexpression as a biomarker for combination treatment strategies in inflammatory breast cancer. Oncotarget. 2017;8(9):14897–14911. Epub 2017/ 01/21. doi: 10.18632/oncotarget.14689. PubMed PMID: 28107181; PMCID: PMC5362453.
   PubMedGoogle Scholar